GSK (GSK) Set to Announce Earnings on Wednesday

GSK (NYSE:GSK) will be announcing its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of $1.19 per share for the quarter. GSK has set its FY 2024 guidance at 1.710-1.740 EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

GSK (NYSE:GSK) last posted its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. GSK had a net margin of 12.87% and a return on equity of 51.48%. On average, analysts expect GSK to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

GSK Stock Up 1.0 %

GSK stock opened at $37.90 on Tuesday. GSK has a one year low of $33.67 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.54 and a current ratio of 0.82. The firm’s fifty day moving average is $41.05 and its 200 day moving average is $41.13. The firm has a market cap of $78.54 billion, a PE ratio of 13.73, a P/E/G ratio of 1.23 and a beta of 0.65.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Friday, August 16th were given a $0.3843 dividend. The ex-dividend date was Friday, August 16th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a dividend yield of 4.06%. GSK’s payout ratio is 55.80%.

Insiders Place Their Bets

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now owns 16,775,691 shares in the company, valued at $134,205,528. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 10.00% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on GSK. Jefferies Financial Group lifted their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, July 2nd. UBS Group cut GSK from a “buy” rating to a “neutral” rating in a report on Monday, July 8th. Barclays raised GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, Argus raised GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Four research analysts have rated the stock with a hold rating, two have assigned a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $50.00.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.